The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
|Slideshows|March 2, 2017
ACTRIMS 2017 Forum: MS Treatment Clinical Trials
Author(s)Samantha J. Peterson
Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.
Advertisement
Presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum included a 10-year follow-up of patients after mitoxantrone treatment, a comparison of no evidence of disease activity in patients treated with ocrelizumab or IFN β-1a, and an evaluation of no evidence of progression in a trial of patients administered ocrelizumab or placebo.
Advertisement
Related to this article
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
3
Headlining Current Advances and Challenges in Multiple Sclerosis Care
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5